Back

From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe

14 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and stroke Oral Anticoagulation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Rafael Salguero-Bodes

12th of October University Hospital, Madrid (Spain)

6 More presentations in this session

Presentation thumbnail
Risk of early device-related thrombosis in post-Watchman cases on low-dose oral-anticoagulation versus dual-antiplatelet therapy
Doctor S. Mohanty (Austin, US)
Abstract Slides Video
Presentation thumbnail
Procedural and clinical outcomes after left atrial appendage occlusion in patients with preprocedural sludge or thrombus: a single-center experience
Doctor H. Alessandrini (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Left atrial appendage occlusion with prior thrombus under OAC: feasibility and safety in a case series of patients with LA dilation and impaired atrial function
Miss F. Beisegel (Berlin, DE) Doctor D. Schoeppenthau (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Left atrial size-based anticoagulation discontinuation after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF Trial
Doctor D. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Long-term efficacy and safety of left atrial appendage closure with WATCHMAN in Japanese nonvalvular atrial fibrillation patients
Doctor M. Nakano (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation and stroke

The Event

Event poster

EHRA 2026

14 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Patient characteristics and real-world outcomes among atrial fibrillation patients treated with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in Spain
thumbnail
Congress Presentation
Real-world use and clinical outcomes among patients with atrial fibrillation using low-dose edoxaban and apixaban in Italy
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources